Introduction
Despite substantial advances made in the last decades, the identification of safe and effective therapeuticsf or the managemento fa cute and chronic pain remains af ormidable challenge in drugd evelopment. The currents tandards of careopioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and gabapentinoids-help many patients,b ut it is estimated that only 25 %ofthem receive adequate pain relief. Moreover,available analgesic drugs exert acute and long-term side effects and can have, as in the case of the opioids,s ignificant potential to induce dependence and addiction. Pain conditions that arise from non-resolving inflammatory pathologies, such as inflammatory bowel disease and arthritis, are particularly challenging owing to the complexity and heterogeneityo ft heir underlying pathogenesis. In such conditions, keyc ontrol nodes that link interactive molecular pathways involved in promoting and maintaining pain, inflammation, and tissue damage might be exploited to achieve greater clinicalb enefits.
[1] In this context, attention has focused on two important families of lipidderived mediators:p rostanoids and endocannabinoids.A ccumulatedevidence points to the presence of multiple biochemical and functional interactions between these signaling pathways, which might offer useful molecular targets for analgesic and anti-inflammatory therapy.
[2]
Herein we outline the scientific rationalef or simultaneously inhibiting two pivotal enzymes of endocannabinoid and prostanoid metabolism-fatty acid amide hydrolase (FAAH) and cyclooxygenase (COX)-and review medicinal chemistry approachesa nd structure-activity relationship (SAR) studies of the multitarget FAAH/COX inhibitors discovered to date.
Interacting Lipid Pathways
Fatty acid ethanolamides (FAEs) such as arachidonoylethanolamide (anandamide), palmitoylethanolamide (PEA), ando leoylethanolamide (OEA) (Figure 1 ) constitute af amily of signaling lipids involved in the regulation of aw ide range of physiologiPain states that arise from non-resolving inflammation, such as inflammatory boweldisease or arthritis, pose an unusually difficult challenge for therapy because of the complexitya nd heterogeneity of their underlying mechanisms. It hasb een suggested that key nodes linking interactive pathogenic pathways of non-resolving inflammation might offer novel targets for the treatment of inflammatory pain. Nonsteroidal anti-inflammatoryd rugs (NSAIDs), which inhibitt he cyclooxygenase (COX)-mediated production of pain-and inflammation-inducing prostanoids, are ac ommon first-line treatment for this condition, but their use is limited by mechanism-based side effects. The endogenousl evels of anandamide, an endocannabinoid mediator with analgesic and tissue-protective functions, are regulated by fatty acid amide hydrolase (FAAH).T his review outlines the pharmacological and chemicalr ationale for the simultaneous inhibitiono fC OX and FAAH activities with designed multitarget agents. Preclinical studies indicate that such agentsm ay combine superior anti-inflammatory efficacy with reducedt oxicity.
cal and pathological processes, including pain andi nflammation.
[3]
The FAEs exert their biological actions by bindingt os elective protein receptors in cells. Anandamide is an endogenous agonisto fG -protein-coupled CB 1 and CB 2 cannabinoid receptors, which mediate the majority of its biological effects. [4] Other pharmacological targets for anandamide, such as transient receptor potential vanilloid type 1( TRPV-1), have been identified, but their physiological significance remains unclear. [5] OEA and PEA do not productively interactw ith cannabinoid receptors, but act by engaging nuclear peroxisome proliferator-activated receptor-a (PPAR-a)a nd, to al esser extent, GPR119.
[6]
The FAEs are produced from phospholipid precursors in membranes through either tonic or 'on-demand' mechanisms. Therefore, the signaling activity of theses ubstances is strictly dependento nt he enzymes responsible for their formation and degradation. [6d, 7] FAAH is the main enzymei nvolved in the degradative hydrolysis of anandamidei ntoa rachidonic acid (AA) and ethanolamine( Figure 2 ).
[8] It is am embrane-bound serine hydrolase localized to intracellular organelles such as microsomes andm itochondria, and is highlye xpressed in brain and liver,among other tissues. [9] Soon after its discovery, [8a, 10] FAAH attracted attention as ap otential target for indirect-acting cannabinoid agents, that is, for compounds that stimulate cannabinoidr eceptors by modulating endogenous anandamidelevels.
[5b] There are multiple precedents that justify the adoption of this indirect strategy (e.g.,n eurotransmitter uptake inhibitors), which are further supported by the fact that direct cannabinoidr eceptor activation causes av ariety of central and peripheral side effects. [11] Conversely,p rotectinga nandamidef rom FAAH-mediated degradationm ight result in am ore physiological activation of cannabinoid receptors-similart ot hat caused by endogenously released anandamide-and mightt hus exert ar estricted, and hopefully favorable, set of pharmacological effects relative to exogenous direct-acting agonists.
[12] Onei mportant piece of evidencei ns upport of this theory comes from experiments with mice lacking the gene encoding for FAAH. These mutant mice display an analgesic and anti-inflammatory phenotype, yet do not showa ny of the typical signs of direct CB 1 receptor activation,s uch as decreased motor activity,l owered body temperature, and catalepsy. [13] Another elementi ns upport of FAAH's value as at arget for analgesic drugs is provided by the preclinical pharmacological profileo fF AAH inhibitors. Severalc lasses of such inhibitors, both reversible and irreversible, have been disclosed in the scientific and patentl iterature.
[14] Af ew of the most investigated classes are exemplified in Figure 3 .
The first selective and systemically active FAAH inhibitor to be disclosed, the O-arylcarbamate derivativeU RB597, [12c, 15] exerts mild anti-hyperalgesic and antiallodynice ffects in animal modelso fa cute and chronic pain. [12c, 16] Interestingly,i ts peripherally restricted analogue, URB937, is markedly more effective in the same models. [17] This is consistent with the presence of ap ro-algesic anandamide-dependentc ircuit in the dorsal spinal cord, whichi sp otentiated by globalF AAH blockade. [18] The compound PF-3845 provides an example of astructurally different class of FAAH inhibitors, based on au rea scaffold, which effectively decreases nociceptive responsesi narat model of chronic inflammatory joint pain (complete Freund's adjuvant,C FA). [19] Improvements on PF-3845 yieldedP F-04457845, which shows excellent pharmacokinetics and is also active in the rat CFAm odel. [20] PF-04457845 progressed into phase II clinical trials for the treatment of osteoarthritic pain, but wasf ound to be ineffective. [21] While disappointing, this negative result is consistent with animal studies suggesting that FAAH inhibitors are only weakly active in pain conditions-such as osteoarthritic and neuropathic pain-that are characterized by profound neuroplastic changes in the central [22] Acute pain states, such as those occurring after surgery or during treatment with antineoplastic drugs, might provide better indications for these agents. [23] In addition to anandamide, FAAH catalyzes the hydrolysis of PEA, OEA (Figure 1) , and other bioactive FAEs. [24] Thus, FAAH inhibition might produce beneficiale ffects in modelso fp ain and inflammation through the contribution of PEA-and OEAmediated activation of PPAR-a. [13b, 25] Moreover,o ther endogenous signaling molecules, such as N-acylglycines and N-acyltaurines,may also contribute. [26] Anandamiden ot only modulates nociception, but can also attenuate neutrophil migration and immune-cell recruitment during inflammation, through the activation of CB 1 and CB 2 receptors.
[27] This may be afactor in the ability of FAAH inhibitors to alleviatei nflammatory symptoms in animal modelso fi ntestinal inflammation. [13c, 28] Innate immuneand other host-defense cells produce avariety of pro-algesic and inflammatorye icosanoids through the action of the bifunctional membrane-bound enzyme, cyclooxygenase( COX) (Figure 2 ). [29] There are two COX isoforms, COX1a nd COX-2, which share~60 %s equence identity and are located on the luminal surfaces of the endoplasmic reticulum and the inner and outer membranes of the nuclear envelope. COX-1 is considered to be ac onstitutive enzymea nd is expressed in most cells of the body.C OX-2 is inducible in many tissues,b ut is also normally expressed in the brain, spinal cord, and kidney. [30] COX-2 inductiono ccurs during tissue damage or inflammation in responset oc ytokines, mitogens,a nd growth factors. [31] Both COX isoformsc atalyzet he first committed step in the pathway that converts membrane-derived AA into al arge family of prostanoids that includes prostaglandin E 2 (PGE 2 ), prostacyclin (PGI 2 )a nd thromboxane A 2 (TXA 2 )( Figure 4). [29] These signaling molecules play important roles in biology throught he activation of selectiveG -protein-coupledr eceptors. Cardiovascular homeostasis, mucosal protection,i nflammation, and cancer are among the diverse physiological and pathological processes modulated by theseagents. [32] Conventional NSAIDs such as ibuprofen, flurbiprofen, diclofenac,a nd indomethacin ( Figure 5 ) are nonselectivei nhibitors of both COX isoforms. [33] Although they are widely prescribed to treat pain, inflammation, and fever,t heir chronic use can produce serious gastrointestinal (GI) and renal damage. [34] Inhibition of constitutive COX-1 activity in the gut mucosa is thought to underpin, at least in part, the toxic effects of NSAIDs on the GI tract.
[34a] This is due to the fact that the tonic production of prostanoids (e.g.,P GE 2 )b ye pithelial cells in the GI mucosa protects these cells from injury,aproperty that is also shared by anandamide( Figure 6 ). [35] To avoid COX-1-dependentG It oxicity,v arious COX-2-preferring inhibitors ('coxibs'; Figure 5 ) have been developed. [29] These compounds are highly effective at reducing pain and inflammation, but exert their own set of potentially severe ad- verse events,w hich are mostly localized to the renal and cardiovascularsystems. [36] COX-2, but not COX-1, converts anandamide into af amily of biologically active prostaglandin ethanolamides ('prostamides').
[37] These agents are pro-algesic and do not interact with cannabinoid or prostanoid receptors, but their mechanism of action is still under investigation. [38] Nevertheless,t hey represent an interesting point of intersection between endocannabinoid and prostanoid systems. The COX-2-mediated transformationo fa nandamidei nto pro-algesic prostamides has led to the hypothesis of the presence of deeper functional connections between the endocannabinoid and prostanoid systems. Confirming this idea, it was shown that genetic deletion or pharmacological blockade of CB 1 receptors prevents the antinociceptivee ffectsp roduced by spinal administration of indomethacin in the mousef ormalin test. [39] Similarr esults were obtained with another NSAID, flurbiprofen, given by intrathecal injection. [40] Further supporting the existence of at ight link between endocannabinoid and prostanoid signaling, local co-administration of ibuprofen and anandamidei nt he rat hind paw was found to produce synergistic antinociceptive effects in the formalin test. [41] The CB 1 receptor antagonist AM251 prevented this synergy. [41] Another study in whicha nandamidew as used along with the selective COX-2 inhibitor rofecoxib or the nonselectiveC OX inhibitor ibuprofen showedt hat these combinations decrease mechanical and thermal hyperalgesia in the rat sciatic nerve ligationm odel. [42] In addition, co-administration of the NSAID ketorolac and the nonselective cannabinoid agonist WIN-555,212-2 exerted additive analgesic effects in the mouse acetic acid test of visceral pain. [43] Collectively,t hese findings strongly imply that the endocannabinoid and prostanoid systems interactatm ultiple levels to regulate nociception.
Additional evidence in support of this hypothesis comes from experiments in which various combinationso fF AAH inhibitors and NSAIDs were tested in animal models.T hese experiments have consistently shown that simultaneous FAAH and COX blockade produces synergistic analgesic responses, along with am arked decrease in NSAID-induced GI damage. In one study,t he FAAH inhibitor URB597 synergistically enhanced the effecto fd iclofenac in the acetic acidt est. [44] In the same report, URB597 was also able to reduce gastric hemorrhages caused by the NSAID. [44] This protectivee ffect was likely due to FAAH blockade, as it was reproduced by genetic FAAH deletion, and required CB 1 receptor activation, because it was absent in mice lacking CB 1 ,b ut not CB 2 ,r eceptors. [44] Like URB597, its peripherally restricted derivative URB937 decreased the number and severity of gastric lesions produced by indomethacin.
[17b] In addition to this gastroprotective effect, URB937 synergistically enhanced the antinociceptive effects of indomethacin in mouse modelso fi nflammatory (carrageenan) and neurogenic (sciatic nerve ligation) pain. Notably, the antinociceptive and gastroprotective effects of URB937 were superior to those of URB597. [44] Finally,c o-administration of diclofenac and PF-3845 attenuated mechanical allodynia in models of inflammatory (carrageenan) and neurogenic pain (sciatic nerve ligation). [45] Blockadeo fe ither CB 1 or CB 2 receptors attenuated the effects produced by the combined administration of FAAH and COX inhibitors. Thesef indings have provided ar ationalef or the design of molecules that carry multitarget FAAH and COX inhibitory activities. Single molecules with such ap rofile are expected to have severala dvantages over combinationt herapies, including more ap redictable pharmacokinetic profile and ad ecreased potentialfor drug-drug interactions.
Approaches to the Design of Multitarget FAAH/COX Inhibitors From single to multiple target inhibitors FAAH is ah omodimer of 64 kDa subunits and belongs to the amidase signature family,w hich is characterized by an unusual Ser241-Ser217-Lys142 catalytic triad. The residues of the catalytic triad interactt hrough an etwork of hydrogen bonds that facilitates protone xchange, activating the nucleophilic residue Ser241( via deprotonation) and the leavingg roup of the substrate (via protonation). Adjacent to the nucleophilics erine side chain is ac ircle of four amide NÀHb onds that form the oxyanion hole of FAAH. In addition to the catalytic core, FAAH is characterizedb yaseries of channels and cavities, which include the membrane access channel (MAC) connecting the active site to an opening located at the membrane anchoring face of the enzyme, the cytosolic port (CP) that allows exit of hydrophilic products from the active site, and the acyl chain bindingp ocket (ABP): an arrower,l onger,a nd more hydrophobic channel that interacts with the acyl chain of the substrate during the catalytic reaction. [14a, 46] COX-1 and COX-2 are homodimers of 70 and 72 kDa subunits, respectively.D imerization is required for structural integrity and catalytic activity. Each subunit containso ne cyclooxygenasea nd one peroxidase actives ite, which are located on opposite sideso ft he catalytic domain, with the heme prosthetic group positioned at the base of the peroxidase site.
Each monomer of COX consists of three structurald omains: as hort N-terminal epidermal growth factor domain, am embrane binding domain (MBD), and al arge, globularC -terminal catalytic domain.T he catalytic domain constitutes the majority of the COX monomer and is the site of substrate bindinga nd NSAID action. The entrance to the COX active site occurs at the base of the MBD and leads to al ong hydrophobic channel that extends deep into the interior of the catalytic domain to form ac onstriction composed of three residues (Arg120, Tyr355, and Glu524)t hat separate the entrance from the active site. Tyr385 is in the COX active site for both isoformsa nd is positioned at the endo ft he channel on the opposite side of Arg120. The peroxidase reaction convertsT yr385 into at yrosyl radicals pecies, which is necessary for activation of the COX reaction cycle. COX-1 and COX-2 active sites are very similar,b ut differ in the presence of as ide pocket in COX-2 located above the Arg120/Tyr355/Glu524 region. This COX-2 side pocket contains Val523 (Ile523 in COX-1) and ac onserved Arg513 (His513 in most COX-1) at the base of the pocket, and it has been pro- posed to be essential for selective COX-2 binding recognition. [47] Despite being evolutionarily unrelated, FAAH and COX have some commonalities, possibly linked to the structural closeness of their substrates, which might be exploitedi nt he design of multitarget inhibitors. In addition, knowledge of the chemical structures of the many FAAH and COX inhibitors now available may be helpful in the rational design of potential binders with desired multitarget pharmacologya nd drug-like properties. [14a, 29] Various drug design approaches have been developed for the identification of multitargeti nhibitors leading to hybrid, fused, or chimeric compounds. [48] The following sectioni llustrates the most relevant strategies and representative examples reportedi nt he scientific and patent literature for the identification of FAAH andCOX inhibitors.
One strategy for the design of multitarget FAAH/COX inhibitors has been the identification of known single-target inhibitors (e.g.,C OX) that also show weak activity at the other target (e.g. FAAH), and are amenable to structural modifications aimed at enhancinga ctivities on that target.S omeN SAIDs directly bind to FAAH and inhibit its catalytic activity.I n1 996, Paria et al. reported that indomethacin decreased anandamide hydrolysisi nm ouse uterus. [49] Subsequent in vitro studies showedt hat suprofen, ibuprofen, fenoprofen, naproxen,k etoprofen, diclofenac, [50] ketorolac, flurbiprofen, [51] and indomethacin [52] inhibit FAAH activity,a lbeit with weak potencies( median inhibitory concentrations (IC 50 values) in the lowt oh igh micromolar range). [50a, 53] These observations stimulated interesti ni dentifying NSAIDbased compounds that also express FAAH inhibitory activity. [50a, 51] In 2003, Cocco et al. described as eries of heteroaromatic ibuprofen anilides bearing substituted pyridine or pyrimidine groups,w hich showed improved analgesic activity and reduced GI sidee ffects relative to the parenta cid. [54] This exploration identified compound 1 (ibu-am5)a st he best analogue. This compound produced complete inhibition of acetic acid induced writhing after oral administration in rats, which was associatedw ith very low ulcerogenic effects relative to its parentmolecule, ibuprofen (Figure 7) .
The reduced GI toxicity of 1 was initially attributedt ot he amidation of the free carboxylic acid group present in ibuprofen, andt he consequent reductiono fi ts local irritating action [55] .Alternatively,weaker GI effects were ascribed to thepotential inhibitory action of this set of amide derivatives on COX-2, as previously reported for ester and amide analogues of aryl acetic and fenamic acids.
[56] Nevertheless, no additional data were reported in this study to support either of these hypotheses.
Am ore complete biochemical evaluation of compound 1, together with 13 additional heteroaromatic amides of ibuprofen and indomethacin, was reported [57] and later integrated with additional comparative data with novel analogues (Figure 7) . [58] In the former report, [57] none of the sixi ndomethacin amide analogues caused complete inhibition of FAAH activity at the concentration tested and, for this reason,w ere not further profiled in COX assays.W ithin the ibuprofen amide series, compound 1 was confirmed to be the most promising analogue, showingamore potent inhibitory activity against rat FAAH, but with as imilar inhibitory profile against ovine COX1a nd COX-2 relative to ibuprofen. It was found that 1 inhibits FAAH activity in an oncompetitive manner with IC 50 values of 4.7 and 2.5 mm at pH 6a nd 8, respectively (for the FAAH assay conditions used, see ref. [59] ). In comparison, the IC 50 values of ibuprofen for FAAH were found to be 130 and 750 mm at pH 6 and 8, respectively.I ni ntact C6 glioma cells, 1 inhibited FAAH with an IC 50 value of 1.2 mm at pH 6a nd 8( for the FAAH assay conditions used, see ref. [60] ). In addition, 1 showed agood selectivity profile against other hydrolases, such as N-acylethanolamine acid amidase and monoacylglycerol lipase.T he effects of 1,i buprofen,a nd indomethacin on the specific binding of [ 3 H]CP55,940 to rat CB 1 and human CB 2 receptors were also investigated. [57] The compound displayed little or no ability to interact with cannabinoid receptors (IC 50 = 41 and 24 mm for 1 toward CB 1 and CB 2 ,respectively).
In light of the overall in vitro pharmacological profile of 1, ar etrospectiveinterpretationofi ts in vivo efficacyi nt he acetic acid model and its reduced ulcerogenic properties [54] was proposed.T he lower GI toxicity of 1 relative to ibuprofen was ascribed more to differences in the physicochemical properties of the two compounds, rathert han to their inhibitory potencies toward COX-1. On the other hand, the different analgesic effect between the two molecules was linked to the ability of 1 to inhibitb oth COX and FAAH.
In as ubsequent study, [58] 1 was compared with ibuprofen and eight additional amide analogues of 1.C ompounds 1 and 2 were the mostp otent inhibitors of rat FAAH relative to ibuprofen (IC 50 = 134 mm), showing IC 50 values of 0.65 and 3.6 mm, respectively (Figure 7) . Different from previous reports from the same group, [57] COX activity was measuredu sing an oxygen electrode assay with commerciallya vailable ovine COX-1 and human recombinant COX-2 as enzyme sources( for the COX assay conditions used, see ref. [61] ). Under those assay conditions, ibuprofen inhibited the activity of ovine COX1t oward AA with an IC 50 value of~29 mm (using ethanol as av ehicle) and~77 mm (using DMSO as av ehicle). Compound 1 was less potent than ibuprofen at inhibiting COX-1, with an IC 50 value of~60 mm (ethanol) and~240 mm (DMSO). Compound 2 inhibited COX-1 with an IC 50 value of~50 mm (ethanol). Ibuprofen, 1,and 2 also showedsubstrate-selectivei nhibition of COX-2, being poor inhibitors of the cyclooxygenation of AA by COX-2 and producing 36, 41, and 18 %i nhibition at the highestc oncentrations tested (300,3 00, and 100 mm,r espectively). However,w hen anandamidew as used as substrate, these compounds werer elatively potent inhibitors of COX-2, with IC 50 valueso f~6( ibuprofen),~19 (1)a nd~10 mm (2).
In addition, 1 was confirmedt ob ea ctive at the dose of 30 mg kg À1 (subcutaneous) in am urinem odel of visceraln ociception, butt his effect was not blockedb ye ither CB 1 or CB 2 receptor antagonists. Twop ossible explanations were proposed:1 )the contribution of analgesia due to the COX inhibitory properties of 1 dominates at the dose and in the model used, or 2) compound 1 is metabolized in vivo to as pecies that retains (or even improves) its COX inhibitory properties, but loses its FAAH inhibitory activity.The authorsexcludedibuprofen being the metabolite, considering that in rats at the lower dose of 20 mg kg À1 (intraperitoneal) ibuprofen is significantly less effective than 1 in the acetic acid test. [54] As malls eries of racemic flurbiprofen and naproxen amide derivatives were also investigated (Figure 8) . [62] Withint his limited set, 3 (flu-am1) and 4 (nap-am1) demonstrated increased inhibitory potency for FAAH, relative to the parentN SAIDs (flurbiprofen and 3,F AAH IC 50 values of 29 and 0.44 mm,r espectively;n aproxen and 4,F AAH IC 50 values of > 100 and 0.74 mm,r espectively)( for FAAH assay conditions, see ref. [59] ). Compounds 3 and 4 werea lso investigated for theira bility to inhibitC OX-1 and COX-2, using the oxygen electrode assay and two differents ubstrates:A A( forb oth isoforms) and2 -AG (for COX-2) (for COX assay conditions, see ref. [61] ). The study confirmedt hat flurbiprofen inhibited the cyclooxygenation of AA catalyzed by ovine COX-1 (IC 50 = 3.6 mm)a nd had little effect on the cyclooxygenation of AA catalyzed by human recombinant COX-2 (IC 50 = 103 mm). Flurbiprofen also inhibited the cyclooxygenation of 2-AG catalyzed by human recombinant COX-2 (IC 50 = 1.3 mm). As imilarp attern of COX-1 and COX-2 inhibition was observed with 3,a lthough in general 2-3-fold higher concentrationsw ere required to produce the same effect as flurbiprofen [COX-1 (AA) IC 50 = 6.6 mm;C OX-2 (AA) IC 50 = 42 mm and COX-2 (2-AG) IC 50 = 1.7 mm,r espectively]. By contrast, 4 was arather poor inhibitor of both COX isoforms [COX-1 (AA) IC 50 = 56 mm;C OX-2 (AA) IC 50 > 100 mm and COX-2 (2-AG) IC 50 = 6.3 mm,respectively].
Compound 3,w hichr eversibly inhibits FAAH, was further investigated in vivof or its ability to inhibit the enzyme in the brain. The compound was administered by intraperitoneal injection in rats 30 min prior to the administration of [ F-labeled FAAH inhibitor. [63] It was postulated thatp retreatment with 3 would prevent the interaction of 18 F-DOPPw ith FAAH. [64] However,administration of 3 at two different dosages had no effect on brain labeling with 18 F-DOPP, which is suggestive of limited penetration.
Using ac omputational strategy, [65] Favia et al. identified the 2-arylpropionic acid, carprofen, as am ultitarget FAAH, COX-1, and COX-2 inhibitor [66] (Figure 9) . In vitro profile studies showedt hat only the S enantiomer of carprofen retained multitarget FAAH and COX inhibition, whereas the enantiomers of 5 and 6 lost activity for one of the two targets. Docking analysis of the putative binding modes of carprofen on FAAH and COX-2 were also reported. [66] In COX-2, it was proposed that carprofen may preferentially interact, via hydrogen bonds formed by its carboxylic group, with Arg120 and Tyr238, while the carbazole scaffold may lie deep in the pocket, facing Tyr385. This putative binding mode is consistent with the experimentally observed modes of interaction of several NSAIDs in complex with either COX-1 or COX-2. In FAAH, carprofen was shown to fit the acyl chain binding channel and establish hydrogen bond interactions with the oxyanion hole through its carboxylic group, although other binding modes could not be excluded. In addition, accurate computational analysiso ft he structural similarities between FAAH and COX-2 were also reported,m apping hydrophobic (i.e.,a cyl chain In 2013, Bertolacci et al. solved the X-ray crystal structure of rat FAAH in complex with carprofen at 2.25 r esolution. [67] This wast he first structural determinationo ft he molecular interactions of an NSAID in complex with FAAH. Diffraction-quality crystals of the FAAH-carprofen complex were obtained by pre-incubating the enzymew ith the O-arylcarbamate inhibitor, URB597. [15] The molecular details of the interactions were investigated using ac ombination of site-directed mutagenesis, WaterLOGSYand FABS NMR spectroscopy,with the goal of providing structurali nsight that might be useful to design novel FAAH/COX inhibitors.
Anumber of dual FAAH/COX inhibitors (mainly COX-2 inhibitors) with indomethacin-like structures are described in patent applicationsf rom Microbia Inc. (changed to Ironwood Pharmaceuticals on April 7, 2008). These compounds are exemplified by 7 and 8 ( Figure 10 ).
[68] However,asystematic SAR analysis for this class of molecules has not been reported.
Rational drug design:m erging strategy
An effective approacht ot he design of multitarget inhibitors is to exploit the presence of structural similarities presenti n selectiveb inders. [48] Compounds with overlapping or integrated pharmacophores are likely to have lower molecular weights and potentially more drug-like physicochemical properties.T he rational design of compound 9,d esigned using this strategy,w as recently reported. [69] This agent combines structuralc ommonalities and pharmacophore groups of two classes of known FAAH and COX inhibitors-Oaryl carbamate FAAH inhibitors such as URB597, [15] and 2-aryl propionic acid NSAIDs such as flurbiprofen [47c, 70] -which share ab iphenyl core as common structural motif (Figure 11 ). Moreover,t he previously reported SAR surrounding these scaffolds support the hypothesis of additional elements of structural overlapping, such as the oxygenated substituents at the 3' position of the Aphenylr ing, corresponding to the carbamate functionality of URB597 [15, 71] and the ether moieties of flurbiprofen analogues 10 a or 10 b,respectively.
[70b]
An initial SAR exploration of the hybrid scaffold 9 around the alkyl substituent of the carbamate group, starting from the hit 11 (IC 50 [mm]: FAAH = 8.2, COX-1 = 7.9, COX-2 > 100) led to the identification of compound 12 (ARN2508)a st he first highly potent and selective multitarget FAAH/COXi nhibitor (IC 50 :F AAH = 31 nm,C OX-1 = 12 nm,C OX-2 = 430 nm). The pharmacological activity of this compound was evaluated in mousem odelso fi nflammatory boweld isease, in whichi ti s knownt hat both FAAH and COX-2 are expresseda ta bnormally high levels.
[72] After oral administration, 12 fully engaged its intendedt argets ande licited ap rofounda nti-inflammatory response, without any overt signs of gastric toxicity.P harmacological and genetice xperiments providede vidence that such responsew as causedb yd ual FAAH/COX inhibition. The results suggest that multitarget FAAH/COXi nhibitors such as 12 might achievemarked anti-inflammatoryefficacy while protecting the GI tract from NSAID-induced damage. [69] The 'double whammy' these compounds produce by blocking both FAAH and COX activities might interrupt the pathological loop established in inflamed tissues by the concomitant upregulation of these enzymes (Figure 12 ).
Future Perspectives
Where do we go from here?I ti sr easonable to expect that multitarget ligands such as ARN2508 (12)w ill continue to be useful in probingt he functional interactions between FAAH and COX, and as am eans to explore the potential therapeutic value of FAAH/COX blockade. In addition to inflammatory bowel disease, where ARN2508 appears to be more effective than standards of therapy and single-target FAAH inhibitors, [69] multitarget FAAH/COX agents might prove valuable in other chronic inflammatory conditions in which FAAH and COX-2 (but also COX-1)a re expressed at pathologically high levels. These include av ariety of peripherala nd central inflammatory states as well as certain forms of cancer. [23, 73] The wide potential applicabilityo ft hese agentsp rovides ag reat therapeutic opportunity,b ut also poses interesting challenges to medicinal chemistry.I na ddition to balanced potency for FAAH andC OX, future molecules should be able to engaget hesep roteins in all compartmentso ft he body,i ncluding the central nervous system,a nd to selectively target FAAH/COX-1 versusF AAH/ COX-2. 
